Navigation Links
PharmAthene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research

In Vitro Assays Show rBChE Suppresses Amyloid Plaque Formation

ANNAPOLIS, Md., April 03, 2007 /PRNewswire/ -- PharmAthene, Inc., a leading biodefense company specializing in the development and commercialization of medical countermeasures against chemical and biological terrorism, announced today that new data from its recombinant butyrylcholinesterase (rBChE) research program were recently presented at the 8th International Conference on Alzheimer's and Parkinson's Diseases in Salzburg, Austria.

New research conducted by Dr. Hermona Soreq and co-workers at the Alexander Silberman Life Sciences Institute at The Hebrew University of Jerusalem, in collaboration with PharmAthene, examined the role of recombinant butyrylcholinesterase (rBChE) in the formation of amyloid plaques, which are believed to play a crucial role in the development of Alzheimer's disease.

The data presented by Drs. Soreq and Langermann, Vice President and Chief Scientific Officer for PharmAthene, show that rBChE can effectively block the formation of amyloid fibrils, precursors to plaque formation in the brain, potentially attenuating neurotoxicity. These data were substantiated by transmission electron microscopy studies, which showed that rBChE dramatically suppressed the formation of fibrils, resulting in thinner and less branched filaments than would normally occur in patients with Alzheimer's disease.

Alzheimer's disease is a progressive neurodegenerative disease, which is estimated to affect more than 4.5 million Americans. One of the hallmarks of Alzheimer's disease is the accumulation of excessive amyloid plaques in areas of the brain that control memory and cognition. Amyloid fibrils are believed to be neurotoxic and interfere with the normal communication between neurons. A growing body of scientific evidence suggests that the accumulation of amyloid plaques and neurofibrillary tangles in the brain may play an
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Pharmathenes Recombinant Butyrylcholinesterase (rBChE) Program the Subject of Promising New Alzheimers Research
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
4. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
5. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
6. Amylin Pharmaceuticals to Present New Data from Broad Diabetes and Obesity Programs at ADA 2007
7. Ambrilia Highlights Encouraging Data for its HIV Integrase Inhibitor Program and Recent Developments at Annual Meeting
8. CuraGen Presents Update on Clinical Development Program for Belinostat
9. Hana Biosciences Presents Data On Two Programs At the American Society of Clinical Oncology Annual Meeting
10. Diatos Announces Positive Clinical Results for its DTS-201 Doxorubicin Prodrug Program
11. OXiGENE Abstracts Published in ASCO Program
Post Your Comments:
(Date:11/24/2014)... , Nov. 24, 2014 Juno ... Breakthrough Therapy Designation to the company,s JCAR015 chimeric ... the treatment of relapsed or refractory B-cell acute ... partner, Memorial Sloan Kettering Cancer Center, where Phase ... "The FDA,s action is important news for ...
(Date:11/24/2014)... 24, 2014  Relmada Therapeutics, Inc. (OTCQB: RLMD), a ... chronic pain, announced today that Sergio Traversa , ... LD MICRO "MAIN Event" Micro-Cap Growth Conference on Wednesday, ... the Luxe Sunset Bel Air Hotel, which is located ... California . The presentation is scheduled ...
(Date:11/24/2014)... -- GlySens Incorporated announced today that it has been awarded ... Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), ... The grant is intended to support human clinical evaluation ... glucose monitoring system.  Final preparations for launch of the ... before the end of 2014. "We are ...
Breaking Medicine Technology:Juno T Cell Therapy For Leukemia Granted FDA Breakthrough Therapy Designation 2Juno T Cell Therapy For Leukemia Granted FDA Breakthrough Therapy Designation 3Relmada Therapeutics To Present At LD MICRO Conference 2GlySens Incorporated Awarded $2 Million Grant from the National Institutes of Health 2
... Oct. 15 Regeneron Pharmaceuticals, Inc. (Nasdaq: ... Annual NewsMakers in the Biotech Industry Conference on Friday, ... a.m. Eastern Time.  The session may be accessed through ... Investor Relations page.  An archived version of the presentation ...
... CINCINNATI, Oct. 15  "This is a significant decision in ... advocates and the entire pharmaceutical industry," commented Benjamin H. ... an en banc hearing was not necessary and that ... plaintiff,s claim that the diet drug Redux (commonly known ...
Cached Medicine Technology:
(Date:11/26/2014)... For those with a New Year’s resolution to ... classes at the University of Colorado Anschutz Health and ... for. The 45- 60 minute classes have just started and ... fitness club memberships. , LES MILLS BODYPUMP™ exercise classes strengthen, ... aimed at fast results , By focusing on low ...
(Date:11/26/2014)... Sonoran Vein and Endovascular nurse, Jennifer E. Hill, ... from The American Association of Nurse Practitioners ... nurse practitioners. The Distinguished Preceptorship Award recognizes the ... significant contribution toward increasing the awareness and acceptance ... (AANP) is the largest full-service national professional membership ...
(Date:11/26/2014)... (HealthDay News) -- Vultures have developed highly specialized ways ... eating dead animals, researchers report. The new research ... faces and in the guts of 50 turkey vultures ... the faces of the vultures had more than 500 ... guts, the study found. The findings suggest that ...
(Date:11/26/2014)... to peanut protein in household dust may increase the ... condition eczema, a new study reveals. About 2 ... allergic to peanuts. And severe eczema in infants has ... researchers noted. The new study included 359 infants ... the amount of peanut protein the children were exposed ...
(Date:11/26/2014)... 25, 2014 (HealthDay News) -- Parents need to take ... concussions, an expert warns. Parents must make sure ... standard, Dr. David Dodick, chair of the American Migraine ... Clinic College of Medicine in Scottsdale, Ariz. in an ... release. Any coach involved with teens sports needs ...
Breaking Medicine News(10 mins):Health News:LES MILLS BODYPUMP™ classes come to the University of Colorado Anschutz Health and Wellness Center 2Health News:Sonoran Nurse Receives Distinguished Preceptorship Award from The American Association of Nurse Practitioners 2Health News:Infants With Eczema May Be More Prone to Peanut Allergy: Study 2Health News:Parents Need to Take Lead on Teen Concussion Prevention 2
... flow may be better conditioned to survive a full-blown ... University of Cincinnati (UC). , In a five-year ... when the heart experiences short periods of stress, either ... activates a protective molecular pathwayknown as JAK-STATthat protects the ...
... WuXi PharmaTech (NYSE:,WX), China,s premier provider of pharmaceutical R&D ... temporarily assume the role of,the Chairman of the Audit ... of the Audit Committee was previously held by Mr. ... his vacation., Mr. Cuong Viet Do has served ...
... drank more heavily than male peers, field study finds ... on-the-scene study of college drinking behavior shows that parties ... while themed parties encourage college women to drink more ... of college drinking have relied largely on individual behavior ...
... - President of cbm, Prof. Allen Foster,announces that cbm ... persons,with disability, not just persons with visual loss., ... Christoffel Blinden,Mission, and Christian Blind Mission, has worked to ... for persons,with visual loss., "The organization has decided ...
... 4 Health Secretary Dr.,Calvin B. Johnson today invited ... exhibit at the Farm Show for free health,screenings, fun ... Body Shop is a fun place for kids and ... running in peak condition," Dr. Johnson said.,"Everyone should stop ...
... International,Associates, Inc, administrator for the HealthShares(TM) Indexes, a ... Funds, today,announced that effective at the opening of ... ARQL ) will replace Coley Pharmaceutical, Inc.,(Nasdaq: ... Index. Coley,Pharmaceutical is being acquired by Pfizer, Inc. ...
Cached Medicine News:Health News:Mini 'stress tests' could help condition heart to survive major attack 2Health News:WuXi PharmaTech (NYSE: WX) Names Temporary Chairman of the Audit Committee 2Health News:College Drinking Games Lead to Higher Blood Alcohol Levels 2Health News:cbm Expanding its Mandate 2Health News:QED International Associates Announces Changes to the HealthShares(TM) Emerging Cancer Index 2
The new CR6-45NM non-mydriatic retinal camera is an ideal diagnostic tool for ophthalmologists, optometrists and other medical professionals, especially when it comes to detecting and monitoring diab...
An ideal choice for film photography. The new TRC-50FXC provides 35mm color and Polaroid capability....
Digital imaging for optical screening: Diabetes, glaucoma macular degeneration, and other retinal disease....
All welded construction for strength and durability. Choice of stainless steel or chrome plated models....
Medicine Products: